Genocea Biosciences, Inc.

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Like Small Cap Stocks < $20?
You should, we just banked a 30% winner in 2 days!
100% secure: your email is never shared, and you may opt out at any time.
Health Technology » Biotechnology
MRNAModerna, Inc. -2.59%204.730.0%$1953.60m
NVAXNovavax, Inc. -1.39%110.8278.2%$804.64m
AMGNAmgen, Inc. 1.95%235.361.4%$611.59m
BIIBBiogen, Inc. 1.11%239.301.8%$512.74m
GILDGilead Sciences, Inc. -0.15%71.771.0%$503.51m
BNTXBioNTech SE -3.44%196.000.0%$496.41m
ILMNIllumina, Inc. 1.41%405.143.3%$455.30m
REGNRegeneron Pharmaceuticals, Inc. -0.14%615.242.7%$435.16m
VRTXVertex Pharmaceuticals, Inc. 3.30%234.061.9%$373.05m
SNSSSunesis Pharmaceuticals, Inc. 2.26%3.170.7%$221.59m
INCYIncyte Corp. 1.67%74.882.4%$172.85m
EXASEXACT Sciences Corp. 4.02%78.4318.0%$156.45m
ARNAArena Pharmaceuticals, Inc. 0.20%92.6513.7%$151.27m
ALNYAlnylam Pharmaceuticals, Inc. 0.34%148.508.2%$147.48m
BMRNBioMarin Pharmaceutical, Inc. 2.34%90.224.2%$114.62m

Company Profile

Genocea Biosciences, Inc. engages in the development and commercialization of cancer vaccines. The firm uses its proprietary technology platform ATLAS, to identify clinically relevant antigens of T cells based on actual human immune responses. Its product candidates include GEN-003, an investigational immunotherapy for the treatment of genital herpes and GEN-009, a neoantigen cancer vaccine. The company was founded by Robert Paull and Kevin J. Bitterman on August 16, 2006 and is headquartered in Cambridge, MA.